Comparison of High-Dose Gemcitabine, Busulfan and Melphalan (GEM/BU/MEL) and BEAM in Concurrent Patient Cohorts with Mature T-CELL NON-Hodgkin's Lymphoma (T-NHL) Receiving an Autologous Stem Cell Transplantation (ASCT)
Year: 2016
Type: article
Abstract: BEAM is considered standard HDC for ASCT for T-NHL. However, pts with relapsed or refractory (R/R) tumors have poor outcomes, underscoring the need for more active HDC regimens. Since 2007 we have developed a new HDC regimen of infusional gemcitabine (administered in a schedule that seeks to optimize its intracellular activation), busulfan and melphalan (Gem/Bu/Mel), exploiting inhibition of DNA damage repair (Nieto, BBMT 2012). Based on our preclinical observations that epigenetic modulation increases the cytotoxicity of Gem/Bu/Mel (Valdez, Exp Hematol 2012), in our recent trials we combined this regimen with vorinostat and azacitidine.
Authors: Yago Nieto, Roland Bassett, Chitra Hosing, Roy B. Jones, Ben C. Valdez, Ashley Kingham, Sairah Ahmed, Amin M. Alousi, Paolo Anderlini, Uday R. Popat, Muzaffar H. Qazilbash, Elizabeth J. Shpall, Partow Kebriaei, Jonathan E. Brammer, Yasuhiro Oki, Michelle A. Fanale, Farzaneh Maadani, Gabriela Rondon, Richard E. Champlin, Borje S. Andersson
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2435989197